Recently, Zhao et al. [28] identified MCPyV small T antigens-induced non-canonical NF-κB signaling as an essential tumorigenic pathway in MCC indicating that the inhibition of NF-κB signaling might be a promising treatment approach for MCPyV-positive MCC patients. The gene discussed is NFKB1; the disease is Merkel cell skin cancer.